Salacia oblonga root decreases cardiac hypertrophy in Zucker diabetic fatty rats: Inhibition of cardiac expression of angiotensin II type 1 receptor

Diabetes, Obesity and Metabolism

Volumn 10, Issue 7, 2008, Pages 574-585

  Huang, T H ^a   He, L ^b   Qin, Q ^c   Yang, Q ^c   Peng, G ^a   Harada, M ^d   Qi, Y ^a   Yamahara, J ^e   Roufogalis, B D ^a   Li, Yuhao ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b SUN YAT SEN UNIVERSITY   (China)

^c MOREHOUSE SCHOOL OF MEDICINE   (United States)

^d KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e Pharmafood Institute   (Japan)

Author keywords

Angiotensin II type 1 receptor; Cardiac hypertrophy; Diabetes; Obesity; Salacia oblonga

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; MANGIFERIN; MESSENGER RNA; PLANT EXTRACT; SALACIA OBLONGA EXTRACT; TELMISARTAN; THYMIDINE; WATER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AYURVEDA; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; EMBRYO; FIBROBLAST CULTURE; GENE EXPRESSION PROFILING; HEART LEFT VENTRICLE; HEART MUSCLE CELL; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; MALE; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; PLANT ROOT; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RAT; SALACIA; SALACIA OBLONGA; ZUCKER DIABETIC FATTY RAT;

EID: 45449106631     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2007.00750.x     Document Type: Article

References (41)

1. Barouch LA, Berkowitz DE, Harrison RW, O'Donnell CP, Hare JM. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 2003; 108: 754-759.
2. de Simone G, Palmieri V, Bella JN et al. Association of left ventricular hypertrophy with metabolic risk factors: The HyperGEN study. J Hypertens 2002; 20: 323-331.
3. Zaman AK, Fujii S, Goto D et al. Salutary effects of attenuation of angiotensin II on coronary perivascular fibrosis associated with insulin resistance and obesity. J Mol Cell Cardiol 2004; 37: 525-535.
4. Li SY, Yang X, Ceylan-Isik AF, Du M, Sreejayan N, Ren J. Cardiac contractile dysfunction in Lep/Lep obesity is accompanied by NADPH oxidase activation, oxidative modification of sarco(endo)plasmic reticulum Ca(2+)-ATPase and myosin heavy chain isozyme switch. Diabetologia 2006; 49: 1434-1446.
5. Golfman LS, Wilson CR, Sharma S et al. Activation of PPARgamma enhances myocardial glucose oxidation and improves contractile function in isolated working hearts of ZDF rats. Am J Physiol Endocrinol Metab 2005; 289: E328-E336.
6. Fredersdorf S, Thumann C, Ulucan C et al. Myocardial hypertrophy and enhanced left ventricular contractility in Zucker diabetic fatty rats. Cardiovasc Pathol 2004; 13: 11-19.
7. Hunyady L, Turu G. The role of the AT1 angiotensin receptor in cardiac hypertrophy: Angiotensin II receptor or stretch sensor? Trends Endocrinol Metab 2004; 15: 405-408.
8. Reaves PY, Gelband CH, Wang H et al. Permanent cardiovascular protection from hypertension by the AT1 receptor antisense gene therapy in hypertensive rat offspring. Circ Res 1999; 85: E44-E50.
9. Kawano H, Do YS, Kawano Y et al. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 2000; 101: 1130-1137.
10. Pitt B. Regression of left ventricular hypertrophy in patients with hypertension: Blockade of the renin-angiotensin-aldosterone system. Circulation 1998; 98: 1987-1989.
11. Thurmann PA, Kenedi P, Schmidt A, Harder S, Rietbrock N. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98: 2037-2042.
12. Li Y, Peng G, Li Q et al. Salacia oblonga improves cardiac fibrosis and inhibits postprandial hyperglycemia in obese Zucker rats. Life Sci 2004; 75: 1735-1746.
13. Huang TH, Peng G, Li GQ, Yamahara J, Roufogalis BD, Li Y. Salacia oblonga root improves postprandial hyperlipidemia and hepatic steatosis in Zucker diabetic fatty rats: Activation of PPAR-α. Toxicol Appl Pharmacol 2006; 211: 225-235.
14. Huang TH, Yang Q, Harada M et al. Salacia oblonga root improves cardiac lipid metabolism in Zucker diabetic fatty rats: Modulation of cardiac PPAR-alpha-mediated transcription of fatty acid metabolic genes. Toxicol Appl Pharmacol 2006; 210: 78-85.
15. Muruganandan S, Gupta S, Kataria M, Lal J, Gupta PK. Mangiferin protects the streptozotocin-induced oxidative damage to cardiac and renal tissues in rats. Toxicology 2002; 176: 165-173.
16. Huang TH, Peng G, Kota BP et al. Anti-diabetic action of Punica granatum flower extract: Activation of PPAR-γ and identification of an active component. Toxicol Appl Pharmacol 2005; 207: 160-169.
17. Huang TH, Peng G, Kota BP et al. Pomegranate flower improves cardiac lipid metabolism in a diabetic rat model: Role of lowering circulating lipids. Br J Pharmacol 2005; 145: 767-774.
18. Li Y, Kishimoto I, Saito Y et al. Guanylyl cyclase-A inhibits angiotensin II type 1A receptor-mediated cardiac remodeling, an endogenous protective mechanism in the heart. Circulation 2002; 106: 1722-1728.
19. Li Y, Kishimoto I, Saito Y et al. Androgen contributes to gender-related cardiac hypertrophy and fibrosis in mice lacking the gene encoding guanylyl cyclase-A. Endocrinology 2004; 145: 951-958.
20. Sanada S, Node K, Minamino T et al. Long-acting Ca2+ blockers prevent myocardial remodeling induced by chronic NO inhibition in rats. Hypertension 2003; 41: 963-967.
21. Abe A, Kiriyama Y, Hirano M et al. Troglitazone suppresses cell growth of KU812 cells independently of PPARgamma. Eur J Pharmacol 2002; 436: 7-13.
22. Davies GF, McFie PJ, Khandelwal RL, Roesler WJ. Unique ability of troglitazone to up-regulate peroxisome proliferator-activated receptor-gamma expression in hepatocytes. J Pharmacol Exp Ther 2002; 300: 72-77.
23. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
24. Watanabe T, Akishita M, He H et al. 17 beta-estradiol inhibits cardiac fibroblast growth through both subtypes of estrogen receptor. Biochem Biophys Res Commun 2003; 311: 454-459.
25. Yoshikawa M, Nishida N, Shimoda H, Takada M, Kawahara Y, Matsuda H. Polyphenol constituents from Salacia species: Quantitative analysis of mangiferin with alpha-glucosidase and aldose reductase inhibitory activities. Yakugaku Zasshi 2001; 121: 371-378.
26. Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC, Cooper ME. Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes 2004; 53: 989-997.
27. Huang CY, Kuo WW, Chueh PJ, Tseng CT, Chou MY, Yang JJ. Transforming growth factor-beta induces the expression of ANF and hypertrophic growth in cultured cardiomyoblast cells through ZAK. Biochem Biophys Res Commun 2004; 324: 424-431.
28. Purcell NH, Tang G, Yu C, Mercurio F, DiDonato JA, Lin A. Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc Natl Acad Sci U S A 2001; 98: 6668-6673.
29. Laufs U, Kilter H, Konkol C, Wassmann S, Bohm M, Nickenig G. Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovasc Res 2002; 53: 911-920.
30. Ogata Y, Takahashi M, Ueno S et al. Antiapoptotic effect of endothelin-1 in rat cardiomyocytes in vitro. Hypertension 2003; 41: 1156-1163.
31. Fujita T, Otsu K, Oshikawa J et al. Caveolin-3 inhibits growth signal in cardiac myoblasts in a Ca2+-dependent manner. J Cell Mol Med 2006; 10: 216-224.
32. Kuo WW, Liu CJ, Chen LM et al. Cardiomyoblast apoptosis induced by insulin-like growth factor (IGF)-I resistance is IGF-II dependent and synergistically enhanced by angiotensin II. Apoptosis 2006; 11: 1075-1089.
33. Hwang GS, Oh KS, Koo HN, Seo HW, You KH, Lee BH. Effects of KR-31378, a novel ATP-sensitive potassium channel activator, on hypertrophy of H9c2 cells and on cardiac dysfunction in rats with congestive heart failure. Eur J Pharmacol 2006; 540: 131-138.
34. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 2004; 63: 423-432.
35. Privratsky JR, Wold LE, Sowers JR, Quinn MT, Ren J. AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase. Hypertension 2003; 42: 206-212.
36. Asbun J, Manso AM, Villarreal FJ. Profibrotic influence of high glucose concentration on cardiac fibroblast functions: Effects of losartan and vitamin E. Am J Physiol Heart Circ Physiol 2005; 288: H227-H234.
37. Ichihara S, Obata K, Yamada Y et al. Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors. J Mol Cell Cardiol 2006; 41: 318-329.
38. Diep QN, Benkirane K, Amiri F, Cohn JS, Endemann D, Schiffrin EL. PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J Mol Cell Cardiol 2004; 36: 295-304.
39. Ogata T, Miyauchi T, Sakai S, Irukayama-Tomobe Y, Goto K, Yamaguchi I. Stimulation of peroxisome-proliferator-activated receptor alpha (PPAR alpha) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts. Clin Sci (Lond) 2002; 103 (Suppl. 48): 284S-288S.
40. Iglarz M, Touyz RM, Viel EC et al. Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. Hypertension 2003; 42: 737-743.
41. Gilde AJ, van der Lee KA, Willemsen PH et al. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res 2003; 92: 518-524.